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Abstract
Background: Accumulation of tumor-infiltrating mast cells (MCs) predicts poor survival in several cancers after
resection. However, its effect on the prognosis of patients with colorectal liver metastases (CRLM) is not known.
Methods: Our retrospective study included 135 patients who underwent potentially curative resection for CRLM
between 2001 and 2010. Expression of tryptase, MAC387, CD83, and CD31, which are markers for MCs, macrophages,
mature dendritic cells, and vascular endothelial cells, respectively, was determined via immunohistochemistry
of resected tumor specimens. The relationship between immune cell infiltration and long-term outcome was
investigated.
Results: The median follow-up time was 48.4 months for all patients and 57.5 months for survivors. Overall
survival (OS) rates at 1, 3, and 5 years were 91.0, 62.4, and 37.4 %, respectively. Five-year disease-free survival (DFS) and
OS rates were 21.6 and 38.1 %, respectively, in patients with high MC infiltration, and 42.6 and 55.6 %, respectively, in
patients with low MC infiltration (p < 0.01 for both DFS and OS). Infiltration of other types of immune cells did not
correlate with survival. Multivariate analyses indicated that hypoalbuminemia and high peritumoral MC infiltration were
significant predictors of unfavorable OS.
Conclusion: High peritumoral MC infiltration predicts poor prognosis in patients who underwent hepatectomy for
CRLM. The number of MCs in metastatic lesions is important for predicting the prognosis of CRLM patients and as an
indication of therapy.
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Background
More than 1 million people are diagnosed with colorec-
tal cancer (CRC) and approximately 0.5 million people
die from this disease each year worldwide [1]. CRC is
the second most common cancer in women and the
third most common cancer in men [2]. Advanced CRC
is frequently accompanied by synchronous or metachro-
nous liver metastases [3]. Despite improvements in
surgical techniques and the introduction of new chemo-
therapy agents, overall survival remains poor for most
patients with colorectal liver metastases (CRLM) [4].
Five-year survival rates after hepatectomy are reported
to range from 33 to 61 % [5–8].
Different types of infiltrating immune cells [mast cells,
(MCs), macrophages (Mφs), dendritic cells (DCs),
neutrophils, and lymphocytes] surround tumors in
variable numbers and have different effects on tumor
progression [9]. We reported the significance of
tumor-infiltrating lymphocytes, such as regulatory T
cells, as a predictor of worse outcome in CRLM pa-
tients [10]. Tumor-infiltrating MCs (TIMs) are con-
sidered a primary host immune response against
cancer. However, their function varies among different
cancers [11–17]. The function of TIMs near CRLM
has never been reported.
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Many tumors secrete stem cell factor (SCF), which at-
tracts MCs to tumor sites [18]. Activation of the c-Kit
pathway leads to MC activation and consequent expres-
sion of angiogenic cytokines [e.g., vascular endothelial
growth factor (VEGF), platelet-derived growth factor
(PDGF), and fibroblast growth factor 2 (FGF-2)] and
tryptase-mediated MC degranulation [19, 20]. Tryptase
is an agonist of protease-activated receptor-2 (PAR-2),
expressed on vascular endothelial cells [21]. Activation
of PAR-2 induces cell proliferation and release of inter-
leukin 6 (IL-6) and granulocyte-macrophage colony
stimulating factor, act as angiogenic molecules [22].
Therefore a strong positive correlation between MC
density and microvascular density in many human and
animal malignancies [23–34].
MCs are classically and conventionally identified via
histochemical methods. Toluidine blue (Undritz stain)
metachromatically stains MC granules red or blue-red
owing to the presence of sulfated proteoglycans (e.g.,
heparin) [35]. MCs can be immunohistochemically
stained with antibodies to c-Kit or proteins in their gran-
ules, such as tryptase or chymase. Primary anti-chymase
and anti-tryptase antibodies produce diffuse cytoplasmic
staining. Tryptase activates protease-activated receptor-2,
and it’s activity stimulates proliferation of colon cancer
cells [36]. Although TIMs may be a useful prognostic
marker in CRC, their significance in CRLM is unclear.
Therefore, the aim of the present study was to determine




Between January 2001 and December 2010, 258 patients
with CRLM underwent initial liver resection at the
Department of Gastroenterological Surgery at Yokohama
City University Graduate School of Medicine. Patients
who could not undergo curative resection (n = 61) or
died during the immediate postoperative period (30 days)
(n = 1) were excluded from our retrospective study. Pa-
tients with a pathologically complete response to neoad-
juvant chemotherapy (NAC) (n = 4) were also excluded
because evaluation of the initial cancer site in the liver
was impossible. Of the remaining 192 patients, 135 with
both clinicopathological data and resected specimens
were analyzed. Primary lesion tissues were collected
for 69 of the 135 patients. Preoperative staging, pre-
operative chemotherapy, hepatectomy procedures, ad-
juvant chemotherapy, and patient follow-up were
previously described [37, 38]. 40 patients received
oxaliplatin, and 17 patients received bevacizumab.
The end of follow-up was defined as the time of the
last follow-up (August 2014) or death. Informed con-
sent for participation in the study was obtained from
participants. Our study was approved by the Yokohama
City University ethics committee.
Immunohistochemistry
Tissue sections (4 μm thick) were deparaffinized in xy-
lene and rehydrated through a series of graded alcohol.
The endogenous peroxidase activity of the specimens
Fig. 1 Representative immunohistochemical staining patterns of formalin-fixed, paraffin-embedded sections of colorectal liver metastases using
monoclonal antibodies to (a) tryptase, (b) MAC387, (c) CD83, and (d) CD31. Original magnification, ×200. Scale bar, 50 μm
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was blocked by incubating the slides in absolute metha-
nol containing 0.3 % hydrogen peroxide for 30 min at
room temperature. Antigen retrieval was carried out via
autoclave pretreatment (120 °C for 5 min) in citrate buf-
fer (pH 6). After washing with phosphate-buffered saline,
specimens were incubated with 10 % rabbit serum albu-
min for 10 min and primary antibody at 37 °C for 1 h.
Mouse monoclonal antibodies were used to recognize
tryptase (Abcam AA1, 1:100; MC marker), MAC387
(Abcam MAC387, 1:1000; Mφ marker), CD83 (Abcam
1H4b, 1:100; mature DC cell marker), and CD31
(Abcam JC 70A, 1:100; vascular endothelial cell marker).
Immunohistochemical reactions were visualized using a
HistoFine kit (Nichirei Pharmaceutical, Tokyo, Japan)
and a DAB kit (Dako, Carpinteria, CA, USA). The sec-
tions were counterstained with hematoxylin and exam-
ined microscopically (Fig. 1a–d). As the negative
control, Mouse IgG1 isotype control (monoclonal mouse
Table 1 Clinicopathological charasteristics of 135 CRLM patients
Variable All cases Peritumoral MCs p value
Low High
Number of patients 135 62 73
Age, years 63.4 ± 10.0 63.4 ± 10.1 63.5 ± 10.0 0.99
Sex [n (%)] 0.60
Male 84 (62.2) 37 (59.7) 47 (64.4)
Female 51 (37.8) 25 (40.3) 26 (35.6)
Location of primary tumor [n (%)] 0.90
Colon 89 (65.9) 41 (66.1) 48 (65.8)
Rectum 46 (34.1) 21 (33.9) 25 (34.2)
Primary lymph node metastases [n (%)] 0.58
Negative 44 (32.6) 22 (35.5) 22 (30.1)
Positive 91 (67.4) 40 (64.5) 51 (69.9)
Timing [n (%)] 0.06
Synchronous 78 (57.8) 30 (48.4) 48 (65.8)
Metachronous 57 (42.2) 32 (51.6) 25 (34.2)
Distribution [n (%)] 0.16
Uniloblar 56 (41.5) 30 (48.4) 26 (35.6)
Biloblar 79 (58.5) 32 (51.6) 47 (64.4)
Tumor number 5.7 ± 6.1 4.8 ± 5.6 6.4 ± 6.4 0.13
Maximum tumor size, mm 39.2 ± 24.6 38.3 ± 23.2 39.9 ± 25.8 0.70
Extrahepatic metastases [n (%)] 0.11
Present 33 (24.4) 11 (17.7) 22 (30.1)
Absent 102 (75.6) 51 (82.3) 51 (69.9)
Preoperative chemotherapy [n (%)] 0.30
Yes 70 (51.9) 29 (47.5) 41 (56.9)
No 65 (48.1) 32 (52.5) 31 (43.1)
Prehepatectomy CRP, mg/L 0.6 ± 1.3 0.7 ± 1.5 0.6 ± 1.2 0.62
Prehepatectomy Alb, g/dL 4.0 ± 0.4 4.0 ± 0.4 4.0 ± 0.5 0.53
Prehepatectomy CEA, ng/mL 201.1 ± 607.1 111.2 ± 341 277 ± 758.0 0.10
Peritumoral MCs 42.2 ± 36.8 11.2 ± 5.2 68.4 ± 31.1 <0.01
Normal liver areal MCs 13.6 ± 9.9 11.4 ± 8.6 15.5 ± 10.6 0.02
Peritumoral Mφs 113.2 ± 105.1 93.4 ± 99.1 130.0 ± 107.7 0.04
Peritumoral mature DCs 7.6 ± 8.7 8.2 ± 6.9 7.1 ± 10.0 0.43
Micro vessel density 39.6 ± 24.9 32.0 ± 16.6 46.0 ± 28.9 <0.01
MCs mast cells, CRP C-reactive protein, Alb albumin, CEA carcinoembryonic antigen, Mφs macrophages, DCs dendritic cells
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IgG1 clone #11711; R&D Systems) was used at the same
concentration, then all other steps were followed.
Immunohistochemical evaluation
Evaluation was performed as previously reported [16, 33,
39, 40]. Cells were counted in each immune cell subset
in the 3 most abundant peritumoral areas, and cell num-
bers were compared. “Peritumoral” was defined as the
border between normal liver tissue and the tumor.
Therefore we defined peritumoral area as a fields which
include tumor three out of ten in view. “Micro vessel
density” was defined as the number of blood vessels.
Positively stained blood vessels with lumen as well as
cell clusters without a lumen and single cells were con-
sidered as individual vessels [41]. Cell counting was per-
formed by two investigators (SS and NK) without
knowledge of the accompanying clinical information and
under the supervision of a pathologist. In cases of dis-
crepancy, a consensus was achieved using a multi-head
microscope.
Statistical analysis
The Kaplan-Meier method was used to estimate Overall
survival (OS) and disease-free survival (DFS). To deter-
mine the optimal cutoff point, a receiver operating char-
acteristic (ROC) curve was drawn for each variable, and
the factor most highly correlated with OS was identified.
The threshold was calculated by determining the Youden
index [maximum (sensitivity + specificity - 1)] from the
ROC curve [42]. Cox regression multivariate models
were used to identify independent prognostic factors.
The Mann-Whitney U and chi square tests were used to
compare cell numbers between subgroups. Statistical
significance was defined as p < 0.05. Analysis was per-




The clinicopathological features of patients enrolled
in this study are summarized in Table 1. The patient
group included 84 men and 51 women with an age
range of 31–83 years (median 63 years). Most pa-
tients (67 %) had primary tumor nodal metastases,
58 % had synchronous liver metastases, and 24 % had
extrahepatic disease at the time of hepatectomy. The
median number of metastatic nodules was 4 (range
1–32), the median follow-up time was 48.4 months,
and the minimum follow-up time was 17.8 months
for survivors. DFS rates at 1, 3, and 5 years were
48.1, 32.6, and 20.7 %, respectively, for the entire
group. OS rates at 1, 3, and 5 years were 91.0, 62.4,
and 37.4 %, respectively.
Tumor-infiltrating immune cells and clinicopathological
features
The distribution of cell numbers for each marker is
shown in Table 1. The average number of TIMs were
84.9 in primary lesion and 42.2 in CRLM. The cutoff
points selected using the maximal Youden index were
26 for peritumoral MCs, 176 for peritumoral Mφs, 17
for peritumoral DCs in CRLM. We found that 54 % (73
of 135) of patients were in the high peritumoral MC
group. There was no significant relationship between
number of peritumoral MCs and clinicopathological fea-
tures, with the exception that the number of MCs in
normal liver, the number of peritumoral Mφs, and
microvessel density were significantly higher in the
high peritumoral group than the low peritumoral
group (p = 0.02, p = 0.04, and p < 0.01, respectively)
(Table 1). There was no significant relationship be-
tween peritumoral Mφ or DC cell counts and clinico-
pathological features including number of peritumoral
vessels (data not shown) or between the number of
TIMs in primary lesions and liver metastasis (r = 0.04,
p = 0.73; Fig. 2). Interestingly, MC counts were not
changed regardless of whether oxaliplatin or bevacizu-
mab is used.
Number of TIMs and survival or recurrence
The DFS and OS curves for each peritumoral marker in
CRLM are shown in Fig. 3. The 5-year DFS and OS rates
were 21.6 and 38.1 %, respectively, in patients with
high peritumoral MC numbers, and 42.6 and 55.6 %,
Fig. 2 Tissue samples from resected primary lesions were stained
with monoclonal antibodies to tryptase. The log-rank test was used
to compare the number of mast cells (MCs) in primary lesions and
metastatic lesions. There was no correlation between these parameters
(r = 0.04, p = 0.73)
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Fig. 3 Tissue samples from resected metastatic lesions were stained with monoclonal antibodies to tryptase, MAC387 and CD83. (a, c, e) Disease-free
survival (DFS) and (b, d, f) overall survival (OS) were determined using the Kaplan-Meier method, and the log-rank test was used to compare
DFS and OS in groups with low and high numbers of peritumoral mast cells (MCs), peritumoral macrophages (Mφs) and peritumoral mature
dendritic cells (DCs)
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respectively, in patients with low MC numbers
(Fig. 3a, b). The differences in survival rates between
the 2 groups were significant (p < 0.01 for both DFS and
OS). On the other hand, there were no significant differ-
ences in DFS and OS between patients with low and high
numbers of Mφs (p = 0.18 and 0.10, respectively) or ma-
ture DCs (p = 0.70 and 0.54, respectively) (Fig. 3c–f ).
Prognostic factors
Fifteen non-immunological and 3 immunological factors
were included in the univariate analysis; these did not
include treatment-related factors. Nine factors were sig-
nificantly associated with OS including sex (male), syn-
chronous hepatectomy, distribution of bilobar liver
metastases, tumor number, extrahepatic disease, NAC,
hypoalbuminemia, high level of pre-hepatectomy carci-
noembryonic antigen, and a high peritumoral MC count.
The factors with a p value of < 0.05 in the univariate ana-
lysis were further assessed in a multivariate analysis
using a Cox proportional hazards model with stepwise
selection. Hypoalbuminemia and high peritumoral MC
infiltration were significant predictors of unfavorable OS
in the multivariate analysis (Table 2).
Discussion
We demonstrated an association between the degree
of peritumoral MC infiltration and clinical outcome
following resection of CRLM. As shown via multivari-
ate analysis, high peritumoral MC infiltration in
CRLM was a significant independent predictor of un-
favorable OS. On the other hand, high peritumoral
MC infiltration in primary lesion was not significant
independent predictor of unfavorable OS. We suggest
that peritumoral MCs induce neo-angiogenesis and
tumor cell proliferation. The prognostic significance
of TIMs in colorectal cancer has been debated and is
controversial [12, 13, 29, 43, 44].
Immunochemical results reflect the type of histological
stain used and the area of the specimen analyzed. Be-
cause Giemsa and toluidine blue [29] are non-specific,
we used anti-tryptase antibody to immunohistochemi-
cally detect tryptase-positive MCs. Tryptase activation
promotes tumor cell proliferation and neo-angiogenesis
by triggering the release of interleukin 6 and granulocyte-
macrophage colony-stimulating factor from MCs. We
thought that tumor-tumor microenvironment interaction
could be evaluated by examining the peritumoral area
rather than the tumor and therefore focused on this area
in this study.
NAC sometimes affects the tumor microenvironment,
for example, by causing lymphocyte infiltration as re-
ported by Nakagawa et al. [10]. In our study, there was a
significant difference in DFS and OS between patients
with low and high MC counts regardless of whether they
Table 2 Univariate and multivariate analyses of overall survival
Variable Univariate Multivariate
p value Hazard ratio 95 % CI p value Hazard ratio 95 % CI
Age, ≧70 years 0.39 0.7 0.3–1.6
Sex, male 0.02 0.4 0.2–0.9 - - -
Timing of hepatectomy, synchronous 0.03 2.4 1.0–5.0 - - -
Distributution, biloblar <0.01 3.4 1.5–7.5 - - -
Number of tumors, ≧4 <0.01 4.2 1.9–9.4 - - -
Diameter of tumors, ≧3 0.28 1.5 0.7–3.1
Primary site, rectum 0.22 1.6 0.8–3.4
Primary lymph node metastases, yes 0.91 1.0 0.5–2.3
Extrahepatic disease, yes <0.01 4.5 1.9–11 - - -
Neoadjuvant chemotherapy, yes <0.01 3.9 1.7–8.5 - - -
CRP, ≧2 mg/L 0.2 2.3 0.6–7.9
Alb, <3.5 g/dL <0.01 6.4 1.6–25 <0.01 14.5 2.2–92
Lymphocytes, <1000 0.55 1.3 0.6–2.9
Neutrophils, ≧6000 0.27 2.8 0.5–17
CEA, ≧100 ng/mL <0.01 3.3 1.4–8.0 - - -
Peritumoral MCs, high <0.01 8.6 3.6–20 <0.01 17.3 4.8–62
Peritumoral Mφs, high 0.13 2.0 0.8–5.0
Peritumoral mature DCs, high 0.34 1.7 0.6–5.3
CI confidence interval, CRP C-reactive protein, Alb albumin, CEA carcinoembryonic antigen, MCs mast cells, Mφs macrophages, DCs dendritic cells
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received NAC (data not shown). Therefore, determining
infiltrating MC numbers is useful after resection of
CRLM even in patients who did not receive NAC.
Consistent with previous studies [24, 29, 32], we found
that high numbers of peritumoral MCs were associated
with high numbers of microvessels in CRLM. The c-Kit
pathway leads to MC activation and consequent expres-
sion of angiogenic cytokines (e.g., VEGF, PDGF, and
FGF-2) and degranulation of MCs [19]. Roles of tumor-
infiltrating Mφs and DCs in some cancers have been re-
ported [39, 40, 45–48]. In this study, peritumoral Mφ
and DC counts were not significant independent predic-
tors of OS in patients with CRLM. Our data, however,
must be interpreted in the context of its study design
limitations. We recognize that tryptase is not the only
MC marker in humans. Therefore, other MC markers
such as chymase, histamine, heparin, VEGF, and PDGF-
β should be tested via immunohistochemistry, and the
relationship between the number of MCs identified via
these markers and OS should be examined.
Ying et al. [49] reported that tumor cells promoted
MC migration in pancreatic ductal adenocarcinoma, and
SCF is a previously reported attractant of MCs [18].
Therefore, we need to clarify whether tumor cells pro-
duce SCF at metastatic lesions.
The relationship between TIM counts, angiogenesis,
and tumor progression suggests that MCs may be a
novel therapeutic target in CRLM. c-Kit tyrosine kinase
inhibitors (e.g., imatinib and masitinib) may be used to
block MC activation and degranulation, and tryptase
inhibitors (e.g., gabexate and nafamostat mesylate) may
be used to prevent the release of tryptase from MC cells
[18, 50–52]. In the future, such drugs may improve the
prognosis of patients with CRLM, particularly those with
high MC infiltration. On the other hand, we did not find
any relationship between the number of MCs in primary
lesions and CRLM. The results of present study show
that the number of MCs in metastatic lesions but not
primary lesions is important for predicting the prognosis
of CRLM patients and as an indication of therapy.
Conclusions
The present study shows that the number of infiltrating
peritumoral MCs is a significant predictor of unfavorable
OS in patients who underwent hepatectomy for CRLM.
Further study is required to identify the molecules that
attract MCs to peritumoral sites in CRLM.
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